Alliancebernstein L.P. maintained its stake in Meridian Bioscience Inc. (NASDAQ:VIVO) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 79,337 shares of the company’s stock at the end of the first quarter. Alliancebernstein L.P. owned about 0.19% of Meridian Bioscience worth $1,095,000 as of its most recent SEC filing.
Other large investors have also added to or reduced their stakes in the company. BNP Paribas Arbitrage SA increased its position in shares of Meridian Bioscience by 12.5% in the first quarter. BNP Paribas Arbitrage SA now owns 8,633 shares of the company’s stock valued at $119,000 after buying an additional 960 shares during the last quarter. Mason Street Advisors LLC increased its position in Meridian Bioscience by 7.2% in the first quarter. Mason Street Advisors LLC now owns 9,868 shares of the company’s stock worth $136,000 after buying an additional 667 shares in the last quarter. Bank of Montreal Can increased its position in Meridian Bioscience by 1,690.1% in the first quarter. Bank of Montreal Can now owns 12,280 shares of the company’s stock worth $169,000 after buying an additional 11,594 shares in the last quarter. UBS Asset Management Americas Inc. bought a new position in Meridian Bioscience during the first quarter worth approximately $179,000. Finally, Louisiana State Employees Retirement System increased its position in Meridian Bioscience by 1.8% in the first quarter. Louisiana State Employees Retirement System now owns 17,200 shares of the company’s stock worth $237,000 after buying an additional 300 shares in the last quarter. Institutional investors and hedge funds own 85.83% of the company’s stock.
Meridian Bioscience Inc. (VIVO) traded down 1.10% during trading on Thursday, reaching $13.45. The company’s stock had a trading volume of 196,979 shares. Meridian Bioscience Inc. has a 52-week low of $10.75 and a 52-week high of $19.85. The stock’s 50-day moving average is $14.93 and its 200 day moving average is $14.02. The firm has a market capitalization of $567.62 million, a price-to-earnings ratio of 26.90 and a beta of 0.89.
Meridian Bioscience (NASDAQ:VIVO) last released its earnings results on Thursday, July 27th. The company reported $0.16 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.16. Meridian Bioscience had a return on equity of 16.93% and a net margin of 10.77%. The business had revenue of $50.14 million for the quarter, compared to analyst estimates of $49.13 million. During the same quarter in the prior year, the company posted $0.21 earnings per share. Meridian Bioscience’s revenue was down 1.0% on a year-over-year basis. On average, analysts predict that Meridian Bioscience Inc. will post $0.67 EPS for the current fiscal year.
The business also recently announced a quarterly dividend, which will be paid on Thursday, August 17th. Investors of record on Monday, August 7th will be issued a dividend of $0.125 per share. The ex-dividend date of this dividend is Thursday, August 3rd. This represents a $0.50 annualized dividend and a yield of 3.72%. Meridian Bioscience’s payout ratio is presently 98.04%.
ILLEGAL ACTIVITY WARNING: This article was reported by StockNewsTimes and is the property of of StockNewsTimes. If you are reading this article on another domain, it was copied illegally and republished in violation of United States and international trademark and copyright law. The correct version of this article can be read at https://stocknewstimes.com/2017/08/10/meridian-bioscience-inc-nasdaqvivo-position-maintained-by-alliancebernstein-l-p-updated.html.
A number of research analysts have recently commented on VIVO shares. BidaskClub downgraded shares of Meridian Bioscience from a “sell” rating to a “strong sell” rating in a research note on Wednesday, August 2nd. Canaccord Genuity upped their price objective on shares of Meridian Bioscience from $13.00 to $15.00 and gave the company a “hold” rating in a research note on Wednesday, May 3rd. Finally, Zacks Investment Research upgraded Meridian Bioscience from a “sell” rating to a “hold” rating in a report on Saturday, April 29th. Three research analysts have rated the stock with a sell rating and four have assigned a hold rating to the stock. The company has a consensus rating of “Hold” and an average price target of $14.75.
Meridian Bioscience Company Profile
Meridian Bioscience, Inc is a life science company engaged in the development, manufacture, sale and distribution of diagnostic test kits for gastrointestinal, viral, respiratory and parasitic infectious diseases, and elevated blood lead levels, and the manufacture and distribution of bulk antigens, antibodies, polymerase chain reaction (PCR)/quantitative PCR (qPCR) reagents, nucleotides, competent cells and bioresearch reagents used by researchers and other diagnostic manufacturers.
Receive News & Ratings for Meridian Bioscience Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Meridian Bioscience Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
